NasdaqCM - Nasdaq Real Time Price USD

Brainstorm Cell Therapeutics Inc. (BCLI)

Compare

0.8760

+0.0810

+(10.19%)

At close: April 17 at 4:00:00 PM EDT

0.8401

-0.04

(-4.10%)

After hours: April 17 at 7:19:58 PM EDT

BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading biotechnology company developing cutting-edge cell therapies for neurodegenerative diseases, today announced the submission of an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration (FDA) for NurOwn®, the company's autologous mesenchymal stem cell therapy for amyotrophic lateral sclerosis (ALS). This important milestone sets the stage for the initiation of BrainStorm's highly anticipated Phase 3b clinical t

PR Newswire 8 days ago

BCLI
+10.19%
Brainstorm Cell Therapeutics Inc (BCLI) Q4 2024 Earnings Call Highlights: Navigating Financial ...

Despite financial constraints, Brainstorm Cell Therapeutics Inc (BCLI) remains committed to advancing its Phase 3b trial for NurOwn, with strategic partnerships and funding avenues in place.

GuruFocus.com 17 days ago

BCLI
+10.19%
Q4 2024 Brainstorm Cell Therapeutics Inc Earnings Call

Q4 2024 Brainstorm Cell Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 17 days ago

BCLI
+10.19%
BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2024, and provided a corporate update.

PR Newswire 18 days ago

BCLI
+10.19%
BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading biotechnology company committed to the development and commercialization of best-in-class autologous cellular therapies for the treatment of neurodegenerative diseases, today announced that it has been granted the exact compliance extension it requested from the Nasdaq Hearings Panel through June 30, 2025, to regain compliance with certain continued listing standards of The Nasdaq Capital Market.

PR Newswire 23 days ago

BCLI
+10.19%
BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call and webcast to update shareholders on financial results for the fourth quarter and year ended December 31, 2024, at 8.30 a.m. Eastern Time on March 31, 2025.

PR Newswire 25 days ago

BCLI
+10.19%
BCLI: Plans Coming Together for Phase 3b Trial of NurOwn® in ALS…

By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Update on Planned Phase 3b Trial of NurOwn® in ALS On December 30, 2024, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) conducted an investor update call to provide a corporate update. The company is currently preparing for a Phase 3b clinical trial of NurOwn in patients with amyotrophic lateral sclerosis (ALS).

Zacks Small Cap Research 3 months ago

BCLI
+10.19%
BrainStorm Issues 2024 Letter to Shareholders

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders.

PR Newswire 3 months ago

BCLI
+10.19%
BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call and webcast on December 30, 2024, at 8:30 a.m. Eastern Time.

PR Newswire 4 months ago

BCLI
+10.19%
BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it has received Notice of Allowance from the U.S. Patent & Trademark Office (USPTO) for patent application 16/981,757 which covers its proprietary exosome technology.

PR Newswire 4 months ago

BCLI
+10.19%
BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will host a key opinion leader (KOL) webinar on Wednesday, December 11, 2024 at 10:00 AM ET. To register, click here.

PR Newswire 4 months ago

BCLI
+10.19%
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2024 and provided a corporate update.

PR Newswire 4 months ago

BCLI
+10.19%
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ: PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This MOU enables

PR Newswire 5 months ago

BCLI
+10.19%
PLUR
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that on October 29, 2024, the Company received written notice from The Nasdaq Stock Market stating that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.

PR Newswire 5 months ago

BCLI
+10.19%
BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of two posters featuring NurOwn® (MSC-NTF0 or debamestrocel) at the 2024 Annual Northeastern Amyotrophic Lateral Sclerosis Consortium (NEALS) Meeting, which took place virtually October 21 – 24. The posters 'Debamestrocel Long-Term Benefits on Survival and Neurodegeneration in ALS Expanded Access Program' and 'An Overview of The Phase 3b Cli

PR Newswire 5 months ago

BCLI
+10.19%
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced its participation in the 2024 Maxim Healthcare Virtual Summit. Chaim Lebovits, President and CEO of BrainStorm, will join Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group, for a Fireside Chat at 9:30 a.m. ET on October 15. During the session, Mr. Lebovits will provide an update on the planned Phase 3b

PR Newswire 6 months ago

BCLI
+10.19%
BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the acceptance of two abstracts featuring NurOwn® (MSC-NTF or Debamestrocel) at the 2024 Annual Northeastern Amyotrophic Lateral Sclerosis Consortium (NEALS) Meeting, to take place October 21 - 24, in-person in Clearwater, Florida and virtually.

PR Newswire 6 months ago

BCLI
+10.19%
Life Sciences Virtual Investor Forum Agenda Announced for September 19th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Virtual Investor Forum to be held September 19th. This event is co-sponsored by Zacks Small-Cap Research Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/3XnsBlt It

GlobeNewswire 6 months ago

BVAXF

AEMD

PLX
BCLI: SPA in Place for Phase 3b Trial of NurOwn® in ALS…

By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Ready to Move Ahead with Phase 3b Trial for NurOwn in ALS On July 8, 2024, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) conducted a conference call to provide an update on the company’s NurOwn™ program. The company is currently preparing for a Phase 3b clinical trial of NurOwn in patients with amyotrophic

Zacks Small Cap Research 7 months ago

BCLI
+10.19%
BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the Second Quarter ended June 30, 2023 and provided a corporate update.

PR Newswire 7 months ago

BCLI
+10.19%

Performance Overview

Return	BCLI	S&P 500 (^GSPC)
YTD	-61.41%	-10.18%
1-Year	-89.19%	+5.19%
3-Year	-98.15%	+20.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Brainstorm Cell Therapeutics Inc. (BCLI)

BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS

Brainstorm Cell Therapeutics Inc (BCLI) Q4 2024 Earnings Call Highlights: Navigating Financial ...

Q4 2024 Brainstorm Cell Therapeutics Inc Earnings Call

BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq

BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update

BCLI: Plans Coming Together for Phase 3b Trial of NurOwn® in ALS…

BrainStorm Issues 2024 Letter to Shareholders

BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update

BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology

BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024

BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting

BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit

BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

BCLI: SPA in Place for Phase 3b Trial of NurOwn® in ALS…

BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Performance Overview